Advanced Breast Cancer Clinical Trial
Official title:
A Multicenter, Open-label, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer
This is a multicenter, open-label, phase Ib study designed to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of CYH33 administered orally in combination with standard-of-care ET ± CDK4/6 inhibitor therapies for the treatment of locally advanced, recurrent or metastatic hormone-receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Patients will be enrolled in two stages, including dose exploration phase (Stage 1) and dose expansion phase (Stage 2) of each cohort.
Status | Not yet recruiting |
Enrollment | 228 |
Est. completion date | December 2022 |
Est. primary completion date | March 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Main Inclusion Criteria: 1. Provide informed consent voluntarily. 2. Male and female patients = 18 years of age. 3. Patient must have a histologically or cytologically documented locally advanced, recurrent or metastatic breast cancer. 4. In case of women, both premenopausal and postmenopausal patients can be enrolled in the study. 5. Confirmed diagnosis of HR+, HER2- breast cancer. 6. For Stage 1 dose exploration phase, patients with or without PIK3CA mutation may be enrolled; For Stage 2 dose expansion phase, patients with PIK3CA mutations are required. 7. Patient must have evidence of disease radiological progression after previous endocrine therapy, or other systemic therapy. 8. Patient has measurable disease per RECIST v1.1. 9. ECOG = 1. 10. Patient must have adequate organ and bone marrow function. Main Exclusion Criteria: 1. Previously received any anticancer therapy within 28 days or 5 times of half-lives prior to the first dose of the study treatment. 2. Previously received treatment with any PI3Ka inhibitor, AKT inhibitor, or mTOR inhibitor. 3. Radical radiation therapy within 4 weeks prior to the first dose of the study treatment. 4. Patient with an established diagnosis of diabetes mellitus. 5. Any other concurrent disease with potential risk of insulin resistance or current use of medication with potential risk of insulin resistance. 6. Patient with clinically significant cardiovascular disease. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Haihe Biopharma Co., Ltd. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dose Limiting Toxicities (DLT) | Incidence rate of DLT in the first cycle (of 28 days). | 28 days | |
Secondary | Safety and tolerability | Type, incidence, duration, severity and seriousness of adverse events (AEs). | 30 months | |
Secondary | Preliminary efficacy-ORR | Tumor objective response rate (ORR) assessed by RECIST v1.1 | 30 months | |
Secondary | Preliminary efficacy-CBR | Clinical benefit rate (CBR) assessed by RECIST v1.1 | 30 months | |
Secondary | Preliminary efficacy-PFS | Progression Free Survival (PFS) assessed by RECIST v1.1 | 30 months | |
Secondary | Pharmacokinetic measures - AUC | Measure the variation of concentration in blood plasma as a function of time | 20 months | |
Secondary | Pharmacokinetic measures - C trough | Measure the minimum (trough) plasma concentration | 20 months | |
Secondary | Pharmacokinetic measures - Cmax | Measure the maximum (peak) plasma concentration | 20 months | |
Secondary | Pharmacokinetic measures - Tmax | Measure of time to reach maximum (peak) plasma concentration | 20 months | |
Secondary | Pharmacokinetic measures - CL/F | Measure apparent total clearance(s) from plasma after administration | 20 months | |
Secondary | Pharmacokinetic measures - Vz/F | Measure apparent volume of distribution during terminal phase | 20 months | |
Secondary | Assess downstream effects of PI3K pathway inhibition on blood glucose | Pre- and post-treatment of blood glucose | 20 months | |
Secondary | Assess downstream effects of PI3K pathway inhibition on C peptide | Pre- and post-treatment of C peptide | 20 months | |
Secondary | Assess the changes of biomarker-PIK3CA | Pre- and post-treatment PIK3CA changes in ctDNA samples. | 20 months | |
Secondary | Assess the changes of biomarker-PTEN | Pre- and post-treatment PTEN changes in ctDNA samples. | 20 months | |
Secondary | Assess the changes of biomarker-KRAS | Pre- and post-treatment KRAS changes in ctDNA samples. | 20 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04653740 -
Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer
|
N/A | |
Completed |
NCT02091960 -
A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05156619 -
Health Care Disparities in Culturally Diverse, Special Needs & Disadvantaged Populations - Bridging the Gap
|
||
Recruiting |
NCT05173103 -
Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer
|
||
Withdrawn |
NCT05191004 -
Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
|
Phase 1/Phase 2 | |
Completed |
NCT00754325 -
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor
|
Phase 2 | |
Recruiting |
NCT04953377 -
PFMT Educational Intervention for Patients With Advancer Breast Cancer
|
N/A | |
Completed |
NCT03240224 -
Bioinformation Therapy for Breast Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT06193525 -
FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test
|
Phase 2 | |
Completed |
NCT03312738 -
A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor
|
Phase 2 | |
Active, not recruiting |
NCT05063786 -
Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)
|
Phase 3 | |
Recruiting |
NCT05655598 -
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
|
Phase 1 | |
Active, not recruiting |
NCT02499146 -
Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT00445458 -
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04456855 -
Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer Patients
|
||
Completed |
NCT04408118 -
First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC
|
Phase 2 | |
Recruiting |
NCT04222413 -
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT03205761 -
Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer
|
Phase 2 | |
Withdrawn |
NCT04316169 -
Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer
|
Phase 1 | |
Completed |
NCT00546104 -
Phase II Dasatinib Study in Advanced Breast Cancer
|
Phase 2 |